Zhou Ping, Wu Hanglin, Lin Xiaona, Wang Shasha, Zhang Songying
Assisted Reproduction Unit, Department of Obstetrics and Gynecology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, Zhejiang, China.
Department of Obstetrics and Gynaecology, Hangzhou Women's Hospital, No. 369 Kun Peng Road, Hangzhou 310008, Zhejiang, China.
Eur J Obstet Gynecol Reprod Biol. 2020 Sep;252:187-192. doi: 10.1016/j.ejogrb.2020.06.057. Epub 2020 Jun 26.
Several recent studies have investigated the relationship between intravenous intralipid and in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) outcomes in women with previous implantation failure. We conducted a systematic review and meta-analysis to evaluate the effects of intravenous intralipid on pregnancy outcomes in women with previous implantation failure. Ovid MEDLINE, the Cochrane Library, Embase and ClinicalTrials.gov were searched up to August 5th, 2019. Randomized controlled trials comparing intravenous intralipid with placebo or no treatment during IVF/ICSI cycles in women with at least one implantation failure were included. Results were presented as risk ratio (RR) with 95 % confidence intervals (CIs). Four studies with 544 participants were included. Live birth rate was statistically higher among the groups of women who received intravenous intralipid (RR 1.98, 95 % CI 1.39-2.80, quality of evidence: low). Intralipid infusion could significantly improve clinical pregnancy rate (RR 1.74, 95 % CI 1.27-2.40, quality of evidence: low). When excluding two studies only published as conference abstracts, there were no significant differences in terms of live birth (RR 1.78, 95 % CI 0.95-3.34, heterogeneity: I² = 25.5 %, quality of evidence: low, Fig. 4A) and clinical pregnancy (RR 1.66, 95 % CI 0.90-3.08, heterogeneity: I² = 47.7 %, quality of evidence: low, Fig. 4B). Adverse events were reported to be rare, but three congenital anomalies were observed in women receiving intravenous intralipid. Administering intravenous intralipid during IVF/ICSI cycles may improve live birth and clinical pregnancy in women with previous implantation failure, such benefit is not significant excluding studies with high risk of bias in the analysis, more studies are needed to evaluate its efficacy and safety especially congenital malformations.
最近的几项研究调查了静脉注射脂质乳剂与既往植入失败女性体外受精/卵胞浆内单精子注射(IVF/ICSI)结局之间的关系。我们进行了一项系统评价和荟萃分析,以评估静脉注射脂质乳剂对既往植入失败女性妊娠结局的影响。检索了截至2019年8月5日的Ovid MEDLINE、Cochrane图书馆、Embase和ClinicalTrials.gov。纳入了在至少有一次植入失败的女性IVF/ICSI周期中比较静脉注射脂质乳剂与安慰剂或不治疗的随机对照试验。结果以风险比(RR)及95%置信区间(CI)表示。纳入了四项研究,共544名参与者。接受静脉注射脂质乳剂的女性组活产率在统计学上更高(RR 1.98,95%CI 1.39 - 2.80,证据质量:低)。脂质乳剂输注可显著提高临床妊娠率(RR 1.74,95%CI 1.27 - 2.40,证据质量:低)。当排除仅作为会议摘要发表的两项研究时,活产(RR 1.78,95%CI 0.95 - 3.34,异质性:I² = 25.5%,证据质量:低,图4A)和临床妊娠(RR 1.66,95%CI 0.90 - 3.08,异质性:I² = 47.7%,证据质量:低,图4B)方面无显著差异。据报道不良事件很少见,但在接受静脉注射脂质乳剂的女性中观察到三例先天性异常。在IVF/ICSI周期中给予静脉注射脂质乳剂可能会改善既往植入失败女性的活产和临床妊娠情况,在分析中排除有高偏倚风险的研究后这种益处不显著,需要更多研究来评估其疗效和安全性,尤其是先天性畸形方面。